Flavored At Large Particles To Improve The Clinical Research Of Cancer-related Depression

Background:2012" Tumor annals in China " shows that Chinese tumor incidence rate of285.91/10million, there are312new cases every year,180.54/10million cancer mortality, each period of experience different degrees of depression. The incidence of3.7%-58%tumor-associated depression reported abroad, domestic report25%-75%. Tumor-associated depression has become the most common mal ignant tumor patients with emotional disorder, affect life quality of patients. Its pathogenesis is not clear, no gold standard for diagnosis and treatment. Clinical study found, Xiaoyao Powder can significantly improve the depressive patients mental state, sure that Xiaoyao Powder in the treatment of psychiatric disorders in the value. Preliminary clinical findings of Jiawei Xiaoyao granule has obvious advantages in improving breast cancer patients with depressive emotion and quality of life, so we proposed the application of Jiawei Xiaoyao granule in the treatment of cancer related depression, provide a clinical basis for more treatment for malignant tumor.Object:Verification of Jiawei Xiaoyao San alleviate depression in patients with malignant tumor associated emotions, improve the quality of life of patients, improve the curative effect of cellular immune function of the patients, to explore the relationship between depression and relationship between IGF-1and malignant tumors at the molecular level, provide more theory as the depression mechanism of malignancy-associated basis.Methods:Using before-after study, using Hamilton Depression Scale (17items), quality of life scale QLQ-C30, the levels of serum IGF-1, T cell subsets was observed. Select the2010.3-2012.12tumor patients during Department of Hematology, Dongzhimen Hospital of Beijing University of Chinese Medicine as the research object. A total of265patients with malignant tumor, diagnosis of64cases of patients with cancer-related depression, into the statistical treatment of62cases,2cases and1cases of falling off, because of medical data is not complete,1cases gave up treatment because of automatic diagnosis was39cases, the relationship between mild depression in cancer patients,19moderate cases,4severe cases. All cases of continuous treatment of2courses (14days for a course), in the treatment of first,14,28days to collect clinical data. SPSS13.0software was used for statistics, statistical data to mean+standard deviation (x±s) said. The t test for comparison, the Paired-saples T Test program for analysis,said P<0.05had statistical significance.Results:Cancer-related depression after28days of treatment the overall efficiency of56.4%. Further stratified comparison:the effective rate was69.2%in mild, moderate efficiency32.8%, severe efficiency25%. The treatment day1compared with14days:quality of life scores in emotional field grade rise, with statistical significance (P<0.05). Treatment days compared with the28day1:quality of life scores in emotional field grade rise, fatigue, insomnia score decline, with statistical significance (P<0.05);Serum IGF-1level decreased,with statistical significance (P<0.05); CD4+, CD4+/CD8+values from the previous rise obviously, statistically significant (P<0.05).Conclusion:Jiawei Xiaoyao San can relieve depression and depression in patients with malignant tumor associated mood to a certain extent, can improve the quality of life of patients, improve the cellular immune function in malignant tumor incidence,reduse IGF-1level. IGF-1verification, tumor-associated depression was positively associated with.